In Reply We thank Shouan and Grover for their interest in our recently published study.1 Regarding the question about the definition of treatment-resistant depression (TRD) used in the study, we would like to emphasize that this was a proof-of-concept study to evaluate the dose response with intranasal esketamine. Larger phase 3 studies are required before the patient population and the utility of esketamine can be fully evaluated in TRD.
Daly EJ, Singh JB. Adjunctive Intranasal Esketamine in Treatment-Resistant Depression—Reply. JAMA Psychiatry. 2018;75(6):654–655. doi:10.1001/jamapsychiatry.2018.0430
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: